1/31/19
Last week Merck announced their V114 investigational 15 strain pneumococcal conjugate vaccine received a Breakthrough Therapy Designation.
This is particularly promising news as it should accelerate the evaluation and approval process. This designation is given to products that show in early clinical trials substantial improvement over currently existing therapies. The vaccine, V114 is designed to prevent invasive pneumococcal disease in patients ages 6 weeks of age to adults. The vaccine contains two serotypes 22F & 33F that are not included in the currently available conjugated pneumococcal vaccine, Prevnar 13. To order Merck vaccines, click here.